CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 90 enrolled
Drug / intervention
Lidocaine geldrug
Likely dose
Lidocaine gel 0.75 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03676725
NCT03676725Early Ph 1Completed
CompareCT.gov

Assessing the Frequency of Lidocaine Ineffectiveness in the General Population vs. Males With ADHD, and Females With ADHD, With or Without PMS

PhenoSolve, LLC·interventional·Posted Sep 19, 2018·Updated Oct 6, 2022

In Brief

A Early Phase 1 clinical trial evaluating Lidocaine gel for ADHD and PMS. Completed, enrolled 90 participants across 2 sites.

Detailed Summary

This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD, PMS
CountriesUnited States
CollaboratorsJacobi Medical Center, Boston Clinical Trials

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedSep 19, 2018
Enrollment StartAug 14, 2019
Primary CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.8 years ago

Interventions

Lidocaine geldrug

Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)